GlassScriptPhysician profile
Chris S Yan
NPI 1578919635
$4,066.77
in general payments reported to CMS, 2019-2025
36 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $383 · 2024: $1,915 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,668 · Education: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,667.74 |
| Education | $399.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $815.63 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $424.49 | 2023-2025 | Airsupra, Fasenra, Breztri |
| Jazz Pharmaceuticals INC. | $365.11 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $241.83 | 2024-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $240.13 | 2023-2025 | Glassia, Cuvitru, Hyqvia |
| Verona Pharma, INC. | $183.15 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $171.90 | 2024-2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $133.74 | 2024-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.33 | 2023-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Insmed, INC. | $112.53 | 2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $112.26 | 2024-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $105.81 | 2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Genzyme Corporation | $77.30 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $70.00 | 2025 | Ultomiris |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $68.75 | 2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $68.58 | 2025 | |
| Zoll Respicardia, INC. | $64.84 | 2024 | Remede System |
| Inspire Medical Systems, INC. | $61.73 | 2024-2025 | Inspire |
| Azurity Pharmaceuticals, INC. | $56.68 | 2025 | Alvesco |
| Mylan Specialty L.P. | $55.85 | 2023-2024 | Yupelri |
| Baxter Healthcare | $52.86 | 2023 | Hillrom - Volara System |
| Lilly USA, LLC | $52.73 | 2025 | Zepbound |
| Viatris Specialty LLC | $45.67 | 2025 | Yupelri |
| Pfizer INC. | $42.56 | 2024-2025 | |
| Philips North America LLC | $35.01 | 2025 | Vest Therapy Und |
| Optinose US, INC. | $27.16 | 2024 | |
| Merck Sharp & Dohme LLC | $23.35 | 2023 | Keytruda |
| Resmed Corp | $20.90 | 2025 | |
| Vifor Pharma, INC. | $20.33 | 2024 | Zemaira |
| Electromed, INC. | $18.26 | 2025 | Smartvest |
| 3b Medical, INC. | $17.25 | 2025 | Luna |
| Phadia US INC. | $16.30 | 2024 | Immunocap |
| Harmony Biosciences LLC | $15.62 | 2025 | |
| Inogen, INC. | $14.15 | 2024 | |
| Ambu INC. | $11.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Yan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.